<DOC>
	<DOCNO>NCT00003865</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth ovarian cancer cell . Hormone therapy use toremifene may fight ovarian cancer reduce production estrogen . PURPOSE : Randomized phase II trial study effectiveness toremifene treat patient recurrent refractory ovarian cancer .</brief_summary>
	<brief_title>Toremifene Treating Patients With Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect toremifene term response rate , duration response , duration survival , toxicity patient chemotherapy resistant papillary carcinoma ovary . - Assess whether dose response effect likely regimen patient . - Assess quality life patient . OUTLINE : This randomize study . Patients receive one two dose oral toremifene daily 4 week . Treatment continue absence disease progression unacceptable toxicity . Quality life assess therapy every 4 week therapy . Patients follow every 12 week death . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm serous papillary carcinoma ovary Recurrent refractory disease follow least one regimen include paclitaxel , cisplatin , carboplatin Measurable disease outside irradiated field No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 16 week Hematopoietic : Absolute neutrophil count least 1,800/mm^3 Platelet count least 125,000/mm^3 No history thrombosis thromboembolic event Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study No concurrent second malignancy prior malignancy within past 5 year , except basal squamous cell skin cancer curatively treat stage I carcinoma cervix No concurrent infection At least 3 day since prior fever ( unless due tumor ) No concurrent severe medical illness No HIV positivity PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No prior tamoxifen antiestrogen therapy Radiotherapy : See Disease Characteristics At least 6 month since prior radiotherapy No concurrent radiotherapy except symptomatic potentially disable bone lesion accompany measurable disease Surgery : Not specify Other : No concurrent anticoagulants No concurrent therapeutic trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
</DOC>